Cerliponase Alfa

Evidence Level: L5

Predicted Indications: 9

Cerliponase Alfa

Pharmacist Assessment Report

Cerliponase alfa: From Neuronal Ceroid Lipofuscinosis to Scheie Syndrome

One-Sentence Summary

Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy, originally used for neuronal ceroid lipofuscinosis (CLN2 disease). The TxGNN model predicts it may be effective for Scheie syndrome, but no clinical trials and no publications currently support this prediction. The prediction rests on model output alone and has a weak mechanistic basis.

Quick Overview

Item	Content
Original Indication	Neuronal ceroid lipofuscinosis; infantile neuronal ceroid lipofuscinosis
Predicted New Indication	Scheie syndrome
TxGNN Prediction Score	0.9998
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, cerliponase alfa is a recombinant form of the lysosomal enzyme TPP1, and it is used to replace the deficient enzyme in CLN2 disease. It is given by the intracerebroventricular route so that it can reach the brain.

Scheie syndrome is the attenuated form of mucopolysaccharidosis I (MPS I). It is caused by a deficiency of a different lysosomal enzyme, alpha-L-iduronidase. TPP1 does not break down glycosaminoglycans, so there is no direct enzyme or substrate match. The high score from the TxGNN model (deep learning) may reflect similarities the model learned between related diseases, not biological evidence. The intracerebroventricular route could in theory address central nervous system involvement, but this has not been tested.

Other predicted indications show the same pattern. Hurler syndrome (also MPS I), cholesteryl ester storage disease, Wolman disease and Gaucher disease each involve a different enzyme deficiency. Several of them already have mechanism-matched therapies. Predictions such as familial encephalopathy with neuroserpin inclusion bodies, juvenile myoclonic epilepsy, proximal myopathy with extrapyramidal signs and an ichthyosis syndrome have no clear lysosomal link to TPP1.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

For the top-ranked prediction (Scheie syndrome), currently no related literature is available.

One publication was retrieved for a lower-ranked prediction, Gaucher disease:

PMID	Year	Type	Journal	Key Findings
41527340	2026	Review	Journal of Inherited Metabolic Disease	Uses Gaucher disease as a model for mapping the natural history of lysosomal storage disorders. It does not evaluate cerliponase alfa and gives no drug-specific evidence.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02484013	BRINEURA	Not available	Not available

Safety Considerations

Please refer to the package insert for safety information. No drug interaction records were found for this drug in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The Scheie syndrome prediction has a high model score but no clinical or published support. Cerliponase alfa replaces TPP1, and Scheie syndrome results from alpha-L-iduronidase deficiency, so the mechanistic rationale is weak. Enzyme replacement therapy that matches the deficient enzyme already exists for MPS I.

To proceed, the following is needed:

The Health Canada package insert, to review warnings and contraindications
Detailed mechanism of action data
Preclinical evidence that TPP1 can affect glycosaminoglycan accumulation or CNS pathology in MPS I models
An assessment of route compatibility and of how the intracerebroventricular route would apply to the proposed indication
A comparison with existing MPS I treatments (enzyme replacement therapy and haematopoietic stem cell transplantation) to define any unmet need
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.